The case in front of me: a residual-solvent screen · hydrolysis · ecnoglutide.
Both of these get recommended confidently by different people, which suggests neither is obviously right.
My constraints are cost, measurement resolution and how much handling I am prepared to do — in roughly that order.
Is there a defensible reason to prefer one, or is this a coin flip?
The honest answer is that mapping is the only routine way to localise a substitution short of full sequencing.
For a short peptide, trypsin may produce too few fragments to be useful. Chymotrypsin, Glu-C or a combination gives better coverage on sequences with few basic residues.
A D-amino-acid substitution has an identical molecular weight to its L counterpart. It is invisible to intact mass, usually invisible to a routine gradient, and detectable by mapping combined with tandem fragmentation or by chiral analysis.
D-amino-acid substitutions being mass-identical is the structural reason intact mass cannot detect them and mapping plus fragmentation can.
Mapping is for mass-neutral problems. That is when it earns its cost.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsWorth being precise here: coverage is the metric that decides whether a map means anything: an eighty per cent map has left a fifth of the sequence unexamined.
Cost is the practical objection. Mapping costs several times a purity assay, which is why it belongs on a first lot from a new supplier rather than on every lot.
Sequence coverage is the headline quality metric. Anything below about ninety-five per cent leaves regions unexamined, and the unexamined regions are where a problem could sit undetected.
A missing expected fragment is as informative as an unexpected one.
The short version: enzymatic digestion, chromatographic separation of the fragments, mass identification of each, and a comparison against the theoretical map.
The result is compared against the theoretical digest of the claimed sequence. A fragment at an unexpected mass localises a problem to a few residues; a missing expected fragment does the same from the other direction.
Put another way, disulfide scrambling gives an unchanged intact mass with different connectivity. Non-reduced mapping — digesting without reducing first — is how the correct pairings are confirmed.
Non-reduced peptide mapping is the accepted approach to confirming disulfide connectivity.
Non-reduced mapping is how you confirm disulfide pairings.
edited 3 May 2025 by b_delacroix — reworded for clarity after a comment
Put another way, this is the most informative single test available for a peptide identity question and it is rarely on a research-grade certificate.
The workflow: reduce and alkylate any disulfides, digest with a specific protease — trypsin cleaving after lysine and arginine is the usual choice — separate the fragments by reverse-phase chromatography, and identify each by mass.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Ask for the coverage figure with any map. Without it the result is not interpretable.
edited 19 May 2025 by plate_count_9k — added the citation requested in comments
Answering this needs to know whether a mass-neutral substitution is plausible for the sequence, since that is the case mapping is for.
Missed cleavages are normal and expected; a map with a moderate number of them is a normal map, not a failed one.
Trypsin cleaving C-terminal to lysine and arginine, except before proline, is the standard specificity and is what makes a theoretical digest predictable.
Commission it on a first lot from a new supplier, not on every lot.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.